• Publications
  • Influence
Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents.
Clinicians and administrators responsible for the health of at-risk populations should implement new approaches for effective monitoring of major modifiable risk factors for medical morbidity and mortality in patients taking second-generation antipsychotics.
Nearly 60,000 uninsured and low-income people with HIV/AIDS live in states that are not expanding Medicaid.
Using national HIV surveillance data and data from the National Health Interview Survey, it is estimated that nearly 115,000 uninsured, low-income people living with HIV/AIDS would be eligible for Medicaid if all states adopted the expansion of Medicaid.
Medication compliance and disease exacerbation in patients with asthma: a retrospective study of managed care data.
Cardiovascular outcomes among HIV-infected veterans receiving atazanavir
Among treatment-naive HIV-infected patients in the Veterans Health Administration initiating ATV-containing regimens, risk of both MI and stroke were significantly lower than in those initiating regimens containing other protease inhibitors, NNRTIs, or INSTIs.
Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting
Abstract Objectives: This study examined total healthcare costs and rates of patients with rheumatoid arthritis (RA) who switch biologic disease-modifying anti-rheumatic drug (bDMARD) therapy in a
Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States
Abatacept was estimated to be more cost effective than rituximab for use in RA from a US third-party payer perspective, however, head-to-head clinical trials and long-term observational data are needed to confirm these findings.
Outcomes and charges of elderly patients with acute myeloid leukemia
Although treatment with CT was associated with increased charges and days in‐hospital, inpatient mortality in the two groups was found to be similar, and in patient mortality did not differ significantly between on‐CT and off‐CT groups.
Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study
In this high-risk population with obesity, NOACs had a varying risk of stroke/SE and MB vs. warfarin, and apixaban and dabigatran had a lower risk of MB.
Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
In this large sample of obese and morbidly obese VTE patients, apixaban had a significantly lower risk of recurrent VTE and MB vs. warfarin when stratified by obesity status post-IPTW.